CardiaCare recently executed a strategic licensing agreement with Dr.Reddy’s Laboratories, a leading multinational pharmaceutical company based in India.
This agreement serves as external validation of our game-changing wearable technology for non-invasive, neuromodulation-based, personalized atrial fibrillation treatment. »

CardiaCare has been selected as one of the top five companies in the value award of MedTech Innovator 2022 cohort

CardiaCare has been selected to take part in MedTech Innovator program. Selected as one of top 50 Startups out of 1000 applicants for the 2022 Cohort in the Tenth Year of World’s Largest MedTech Accelerator Program

CardiaCare successfully completed it’s First in Human Clinical trial in Atrial Fibrillation (AF) patients arriving to the emergency room of the Chaim Sheba Medical Center. Patients have received the CardiaCare RR2 device for 8 weeks of home-care neuromodulation therapy and monitoring. The results demonstrated a high device safety profile, a significant acute reduction in AF precursor arrythmia events as well as long term reduction in AF recurrence rates after discharge from the hospital. In this real-life population study the home-care compliance with with device monitoring and therapeutic capabilities was extremely high.

TEL AVIV, Israel, Dec. 16, 2019 /PRNewswire/ — CardiaCare, a startup developing wearable therapeutic devices for treating and monitoring AFib, announced today that it has been named the First Prize winner of the 2019 Innovation in Cardiovascular Interventions (ICI) Technology Parade in Tel Aviv. CardiaCare presented its innovative product, a wearable neuromodulation (nerve stimulation) device for monitoring and treating AFIb. Read More.